Intuitive Surgical Inc (ISRG) - Stock Report

The latest quarter supports the franchise, not the price. Q1 2026 revenue rose 23% to $2.77 bn, da Vinci procedures grew 16%, Ion procedures grew 39%, and recurring revenue reached $2.37 bn, or 86% of total revenue. The installed base also expanded: 431 da Vinci systems were placed, including 232 da Vinci 5 systems, and the da Vinci installed base reached about 11,395 systems. The quarter is encouraging, but it should not be annualized mechanically: utilization improved 3% and product gross margin recovered, while the cash bridge was quarter-specific because operating cash flow of $912 m, less $103 m of property and equipment purchases, did not cover $1.12 bn of buybacks.

The key macro issue is not hospital spending in isolation, but whether capital budgets, reimbursement and operating-room utilization keep converting Intuitive’s installed base into recurring instruments, accessories and service revenue: if they do, da Vinci 5 and Ion can support retained cash per share; if they do not, the same installed-base growth can pressure margins, buyback returns and the premium multiple.

Intuitive develops and sells robotic-assisted surgical platforms, led by da Vinci for minimally invasive surgery and Ion for lung biopsy. The value stack is not just hardware. Systems create the installed base, instruments and accessories monetize each procedure, services keep the fleet productive, leasing expands hospital access, and training plus digital support makes surgeon adoption harder to displace.

The company reports one operating segment, but the per-share economics have distinct roles. Da Vinci multiport is the cash engine because it carries the largest installed base and procedure pool. Da Vinci 5 is the upgrade and utilization test: it can lift fleet capability and average selling price, but it also brings launch, manufacturing and depreciation burden. Single Port expands the addressable procedure set. Ion is a faster-growing adjacency in lung biopsy, still smaller than da Vinci but useful because it proves whether Intuitive can build a second procedure ecosystem.

Hospitals buy systems only when the procedure economics make sense. That makes the model different from a one-off capital-equipment vendor: capital placements matter, but the more durable test is whether systems already in hospitals are used more often and whether each use generates instrument, accessory, lease and service revenue without eroding margins.